Patents by Inventor Nick Knudsen

Nick Knudsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
    Publication number: 20200164085
    Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 28, 2020
    Inventors: Philip E. Brandish, Robert M Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
  • Phosphate based linkers for intracellular delivery of drug conjugates
    Patent number: 10550190
    Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 4, 2020
    Assignees: Merck Sharp & Dohme Corp., Ambrx, Inc.
    Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20200031894
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 30, 2020
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • ANTI-CD70 ANTIBODY DRUG CONJUGATES
    Publication number: 20190338039
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: December 18, 2018
    Publication date: November 7, 2019
    Applicant: Ambrx, Inc.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason Pinkstaff
  • MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
    Publication number: 20190248863
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 15, 2019
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIIVAN
  • Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
    Patent number: 10377805
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 13, 2019
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 10253083
    Abstract: Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 9, 2019
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS
    Publication number: 20190071483
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: October 4, 2016
    Publication date: March 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • Modified Bovine G-CSF Polypeptides And Their Uses
    Publication number: 20190071482
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: March 7, 2019
    Inventors: Anna-Maria A. HAYS PUTNAM, Nick KNUDSEN, Thea NORMAN, Alan KODER, Vadim KRAYNOV, Lillian HO, Peter C. CANNING
  • Anti-CD70 antibody drug conjugates
    Patent number: 10208123
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: February 19, 2019
    Assignee: Ambrx, Inc.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason K. Pinkstaff
  • Modified bovine G-CSF polypeptides and their uses
    Patent number: 10138283
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 27, 2018
    Assignees: AMBRX, INC., ELANCO US INC.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Ho, Peter C. Canning
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20180311368
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: March 30, 2018
    Publication date: November 1, 2018
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
    Patent number: 10105447
    Abstract: Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 23, 2018
    Assignees: ELANCO US INC., AMBRX, INC.
    Inventors: Michael Bledsoe, Peter Connor Canning, Michael Deguzman, Nick Knudsen, Ianina Valenta
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20180298073
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9975936
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 22, 2018
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Method of treating heart failure with modified relaxin polypeptides
    Patent number: 9962450
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 8, 2018
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified leptin polypeptides and their uses
    Patent number: 9938333
    Abstract: Modified human leptin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: April 10, 2018
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Anna-Maria A. Hays Putnam, Nick Knudsen, Jason Pinkstaff, Heather Myler, Lorraine Sullivan
  • THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES
    Publication number: 20170226178
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 10, 2017
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AMHA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES
    Publication number: 20170182181
    Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
    Type: Application
    Filed: March 30, 2015
    Publication date: June 29, 2017
    Applicants: Merck Sharp & Dohme Corp., Ambrx, Inc.
    Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
  • Modified FGF-21 Polypeptides and Their Uses
    Publication number: 20170096463
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 6, 2017
    Inventors: Thomas P. CUJEC, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov